Yesterday, Myriad Genetics, Inc. (NASDAQ:MYGN) saw two of its insiders dispose of company shares. The talk is of President and Chief Executive Officer, Peter Meldrum, who completed a sale of 24,000 shares of Common Stock, directly, for a price of $39.5 per share. The insider used a non-qualified stock option for the disposition and the transaction was effected pursuant to a Rule 10b5-1 trading plan.
Jerry Lanchbury, Chief Scientific Officer at Myriad Genetics, also completed a disposition, unloading 20,000 shares of Common Stock for $39.85 per share. This sale was also executed directly and via the use of a non-qualified stock option. However, this was certainly not Lanchbury’ first stock sale, as the insider disposed of 54,676 shares of Common Stock back in April, paying a price of $39.65 per share.
On another note, this quarter showed some changes amongst hedge fund positions, with a new candidate on the rise: David Cohen and Harold Levy’s Iridian Asset Management. The hedge fun entered a new shareholding position with over 2.5 million Myriad shares, estimated at $322.6 million.
Disclosure: none
